Galactomannan C

Drug Profile

Galactomannan C

Alternative Names: DAVANAT®; GM-CT-01

Latest Information Update: 07 Sep 2015

Price : $50

At a glance

  • Originator Pro-Pharmaceuticals
  • Developer Galectin Therapeutics; Icahn School of Medicine at Mount Sinai; Pro-Pharmaceuticals
  • Class Antineoplastics; Mannans; Polymers
  • Mechanism of Action Galectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Colorectal cancer

Highest Development Phases

  • Preclinical Hepatic fibrosis
  • No development reported Biliary cancer; Malignant melanoma
  • Discontinued Breast cancer; Colorectal cancer

Most Recent Events

  • 07 Sep 2015 No recent reports of development identified - Malignant melanoma (Combination therapy, Metastatic disease) in Belgium and Luxembourg (IV)
  • 13 Aug 2015 Galectin Therapeutics receives patent allowance for use of pectin compounds in reduction of fibrosis in multiple diseases in USA
  • 27 Apr 2013 Preclinical trials in Hepatic fibrosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top